TLSIW · Insider Trading
TriSalus Life Sciences, Inc. Warrant
Every open-market purchase and sale reported by TLSIW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-19 | Richard Marshak | Chief Commercial Officer | Sell | −543 | −$1.45K |
| 2026-05-18 | David Patience | Chief Financial Officer | Buy | +7,100 | +$17.25K |
| 2026-05-18 | Mats Wahlstrom | Director | Buy | +60,000 | +$151.80K |
| 2026-05-18 | Mary T Szela | CEO and President | Buy | +39,682 | +$102.78K |
| 2026-05-18 | Gary B. Gordon | Director | Buy | +10,000 | +$24.60K |
| 2026-05-18 | Michael P Stansky | Director | Buy | +610,000 | +$1.52M |
| 2026-05-15 | Michael P Stansky | Director | A | +43,590 | — |
| 2026-05-15 | Gary B. Gordon | Director | A | +52,754 | — |
| 2026-05-15 | Kerry R Hicks | Director | A | +28,201 | — |
| 2026-05-15 | David J Matlin | Director | A | +51,266 | — |
| 2026-05-15 | Mats Wahlstrom | Director | A | +71,828 | — |
| 2026-05-15 | William Valle | Director | A | +52,754 | — |
| 2026-04-20 | Equity AB Frankenius | 10%+ Owner | C | +759,000 | — |
| 2026-04-01 | David J Matlin | Director | C | +330,000 | — |
| 2026-03-20 | Mary T Szela | CEO and President | Sell | −20,302 | −$79.38K |
| 2026-03-20 | Richard Marshak | Chief Commercial Officer | Sell | −3,457 | −$14.21K |
| 2026-03-20 | Bryan F. Cox | Chief of Research | Sell | −3,184 | −$13.09K |
| 2026-03-20 | Jennifer Stevens | Chief Regulatory Officer | Sell | −3,530 | −$14.51K |
| 2026-03-20 | Jodi Devlin | Chief of Clinical Operations | Sell | −3,207 | −$13.17K |
| 2026-02-23 | Mary T Szela | CEO and President | Buy | +30,487 | +$125.00K |
| 2026-02-23 | Gary B. Gordon | Director | Buy | +9,756 | +$40.00K |
| 2026-02-23 | William Valle | Director | Buy | +30,487 | +$125.00K |
| 2026-02-23 | David Patience | Chief Financial Officer | Buy | +3,657 | +$14.99K |
| 2026-02-23 | Michael P Stansky | Director | Buy | +361,098 | +$1.48M |
| 2026-02-11 | Michael P Stansky | Director | A | +92,537 deriv. | — |
| 2025-11-25 | Bryan F. Cox | Chief of Research | A | +40,000 | — |
| 2025-11-25 | Richard Marshak | Chief Commercial Officer | A | +60,000 | — |
| 2025-11-25 | David Patience | Chief Financial Officer | A | +65,000 | — |
| 2025-11-25 | Jodi Devlin | Chief of Clinical Operations | A | +50,000 | — |
| 2025-11-25 | Jennifer Stevens | Chief Regulatory Officer | A | +50,000 | — |
| 2025-11-25 | Mary T Szela | CEO and President | A | +550,000 | — |
| 2025-08-29 | David Patience | Chief Financial Officer | A | +248,899 deriv. | — |
| 2025-08-15 | David Patience | Chief Financial Officer | A | +200,000 | — |
| 2025-06-27 | Kerry R Hicks | Director | A | +15,000 deriv. | — |
| 2025-06-27 | David J Matlin | Director | A | +15,000 deriv. | — |
| 2025-06-27 | William Valle | Director | A | +15,000 deriv. | — |
| 2025-06-27 | Arjun JJ Desai | Director | A | +15,000 deriv. | — |
| 2025-06-27 | Mats Wahlstrom | Director | A | +15,000 deriv. | — |
| 2025-06-27 | Gary B. Gordon | Director | A | +15,000 deriv. | — |
| 2025-06-27 | Sean Murphy | Director | A | +15,000 deriv. | — |
| 2025-05-21 | Sean Murphy | Director | A | +44,884 | +$232.50K |
| 2025-05-21 | Jodi Devlin | Chief of Clinical Operations | MIXED | +19,367 | +$100.32K |
| 2025-05-21 | Bryan F. Cox | Chief of Research | MIXED | +10,958 | +$56.76K |
| 2025-05-21 | James Emmett Young | Chief Financial Officer | A | +13,175 | +$68.25K |
| 2025-05-21 | Jennifer Stevens | Chief Regulatory Officer | MIXED | +19,751 | +$102.31K |
| 2025-05-21 | Richard Marshak | Chief Commercial Officer | MIXED | +14,831 | +$76.82K |
| 2025-02-19 | Mary T Szela | CEO AND PRESIDENT | A | +21,089 | — |
| 2025-02-19 | Jodi Devlin | Chief of Clinical Operations | A | +5,272 | — |
| 2025-02-19 | Richard Marshak | Chief Commercial Officer | A | +7,644 | — |
| 2025-02-19 | Bryan F. Cox | CHIEF OF RESEARCH | A | +11,450 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Equity AB Frankenius | 10%+ Owner | 6,989,748 | $5.24M |
| Michael P Stansky | Director | 1,640,420 | $1.23M |
| Mats Wahlstrom | Director | 1,592,002 | $1.19M |
| David J Matlin | Director | 1,323,210 | $992.41K |
| Mary T Szela | CEO and President | 1,065,215 | $798.91K |
| Kerry R Hicks | Director | 624,635 | $468.48K |
| Sean Murphy | Chief Manuf, Strategy&Bus Dev. | 481,524 | $361.14K |
| David Patience | Chief Financial Officer | 275,757 | $206.82K |
| Arjun JJ Desai | Director | 247,127 | $185.35K |
| Bryan F. Cox | Chief of Research | 163,994 | $123.00K |
| Richard Marshak | Chief Commercial Officer | 125,101 | $93.83K |
| Jennifer Stevens | Chief Regulatory Officer | 124,110 | $93.08K |
| Jodi Devlin | Chief of Clinical Operations | 99,409 | $74.56K |
| William Valle | Director | 83,241 | $62.43K |
| James Emmett Young | Chief Financial Officer | 79,663 | $59.75K |
| Gary B. Gordon | Director | 72,510 | $54.38K |
| Liselotte Hyveled | Director | 10,040 | $7.53K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TLSIW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.